Document is current
Any future updates will be listed below
-
Authors
Durante, Michael A. https://orcid.org/0000-0003-3137-6847
Kurtenbach, Stefan https://orcid.org/0000-0002-7445-596X
Sargi, Zoukaa B.
Harbour, J. William
Choi, Rhea
Kurtenbach, Sarah
Goss, Garrett M.
Matsunami, Hiroaki
Goldstein, Bradley J. https://orcid.org/0000-0002-9612-1696
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (CA125970)
U.S. Department of Health & Human Services | NIH | National Institute on Deafness and Other Communication Disorders (DC013556, DC016859)
- License Information
-
More Information
Article History
Received: 24 May 2019
Accepted: 3 January 2020
First Online: 17 February 2020
Competing interests
: J.W.H. is the inventor of intellectual property related to prognostic testing for uveal melanoma. He is a paid consultant for Castle Biosciences, a licensee of this intellectual property and receives royalties from its commercialization. The other authors do not have any potential competing interests.
